Anaplastic Large Cell Lymphoma: Atlas of Blood Cancer Genomes
Anaplastic large cell lymphoma (ALCL) comprises biologically distinct entities based on ALK translocation status. We profiled clinical features and tumor genomics of 118 ALCL biopsy samples (n=54 ALK+, n=64 ALK-negative) to identify factors that influence survival outcomes. ALK‑negative patients showed inferior overall survival (OS) compared to ALK+ patients (p<0.05). ALK‑negative ALCL that harbored TP53 mutations had the poorest OS compared to ALK+ or TP53‑wild type, ALK-negative patients (p<0.05). Mutational burden and copy number variation (CNV) burden were highest in ALK‑negative, TP53-mutated cases compared with either of the other groups (p<0.05). Pathway analysis showed enrichment of genes involved in epigenetic regulation, DNA‑damage repair, and immune/JAK‑STAT signaling in ALK‑negative tumors. On the other hand, NOTCH pathway genes were more frequently mutated in ALK+ cases. Lollipop plots confirmed canonical STAT3 SH2 hotspot variants (Y640F) and dispersed JAK1 kinase domain mutations. This study implicates TP53 loss as a key determinant of genomic instability and clinical behavior in ALK-negative ALCL. Stratification by both ALK translocation and TP53 mutational status may refine risk assessment in this disease
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000001937 | Illumina NovaSeq X | 63 | |
| EGAD50000001938 | Illumina NovaSeq X | 62 | |
| EGAD50000001939 | Illumina NovaSeq X | 65 |
